🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Very nice discussion by Mark Awad putting KN-671 into context & asking important Qs about clinical implications in an increasingly crowded setting. #ASCO23 #LCSM #OncoAlert

How can we improve lung cancer screening uptake? Prioritizing patient navigation, clinical team education, and enhanced EHR processes is key ASCO UTSW Simmons Cancer Center UTSW Hematology & Oncology

Roy Herbst smiled at the history-making results of ADAURA #ASCO23 Plenary. The 1st demonstration of OS benefit to adj EGFR TKIs. To me, this is clinically meaningful & practice changing. Now we have to learn how to tell who is at risk for this disease and SCREEN them!

Dr. Rebecca Heist with an INCREDIBLY impt point on redundancy of IO-based trial developmnt in NSCLC. Is this optimal use of limited resources (financial, person power, brain power, regulatory)? Criticaly, pts who experience IO-mediated tox are largely excluded from these studies.

What is the role of AXL inhibition in advanced NSCLC? Check out our phase 1 trial of bemcentinib + docetaxel in previously treated advanced NSCLC Lung Cancer Journal Brekkenlab Jonathan Dowell UTSW Simmons Cancer Center UTSW Hematology & Oncology sciencedirect.com/science/articl…

Important result on striking disparity in incidence of lung cancer in women than men these days: The Burden of Lung Cancer in Women Compared With Men in the US jamanetwork.com/journals/jamao… #LCSM

Last Chance! Join us 10/30 from 8:30-10PM EDT for a popular CME program! A game show-style quiz competition featuring key opinion leaders as contestants & focus on the challenges of managing cancer pain using the Evolve KOL Knockout case-based format:bit.ly/KOLKnockout23 #LCSM

Check out our recent JAMA Oncology Research Letter. We must consider how this trend impacts contemporary cancer care delivery. UTSW Simmons Cancer Center UTSW Hematology & Oncology UTSW Internal Medicine

Many updates in the 1.2024 National Comprehensive Cancer Network (NCCN) NSCLC guidelines including: - amivantamab + carbo/pem preferred 1L for EGFR exon 20 (PAPILLON) - amivantamab + carbo/pem for #EGFR post osimertinib (MARIPOSA2) - repotrectinib for 1L #ROS1 (TRIDENT) - atezolizumab monotherapy for PS3 (IPSOS)

What a powerful opening at #TexasLung24!! Truly a privilege to provide care for our patients with lung cancer 🙏🏽

Great to present at #TexasLung24 and connect with my thoracic oncology colleagues! #LCSM TLC Conference UTSW Simmons Cancer Center UTSW Hematology & Oncology

Not to steal the thunder from the oral session today, but this is the CROWN PFS curve, more or less flat between 2-5 years and still 60% progression free at 5 years! #ASCO24 #LCSM Is it worth the side effects of lorlatinib to turn ALK+ NSCLC into CML?

What an incredible honor to present our IIT on osimertinib + SABR in advanced EGFR+ NSCLC at ASCO this year! Grateful for the opportunity to share insights and collaborate with the incredible oncology community. UTSW Simmons Cancer Center UT Southwestern Medical Center

Beautiful, eloquent and poised discussion of #LAURA by Lecia Sequist, MD, MPH emphasizing the importance of PFS benefit in this population, preventing morbidity from CNS Mets while balancing the issue of cost, QoL and biomarkers 👏🏽🫁 ASCO #ASCO24 OncoAlert

Dr. Lauren Averett Byers, MD with a wonderful discussion of ADRIATIC at #ASCO24 - highlighting a much greater impact on OS with immunotherapy in the limited stage setting than seen in extensive stage.

Excellent overview of recent perioperative strategies in kidney cancer from QianJanieQin #OncLiveSOSS UTSW Simmons Cancer Center UTSW Hematology & Oncology

Educational morning learning from my GU oncology colleagues! Tian Zhang, MD, MHS QianJanieQin Petros Grivas #OncLiveSOSS UTSW Simmons Cancer Center UTSW Hematology & Oncology

What a line up discussing new&exciting therapies in #lung cancer with highlights in the perioperarive space, utility of #osimertinib #rybervant for #EGFR patients, and #ADC for #mNSCLC with Sheena Bhalla SawsanRashdanMD Dr. David Gerber Tian Zhang, MD, MHS OncLive.com UTSW Simmons Cancer Center

Immunotherapy session this morning 🔥 #TexasLung25 Sheena Bhalla Hossein Borghaei, DO Dr. Julie Brahmer LudaBazhenovaMD Ferdinandos Skoulidis Shirish Gadgeel Jeff Yorio, MD

Lung & Order starts NOW 👩‍⚖️— The trial of the century: Frontline treatment for EGFR positive mNSCLC #TexasLung25 TLC Conference